Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

被引：0
|
作者：
Yuan Hong
Xichuang Chen
Yuanquan Hong
Xingfang Xiao
Yan Wang
Xiaohong You
Jingyi Mi
Tao Zhou
Panpan Zheng
Zhihu Huang
机构：
[1] Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital),Department of Pharmacy
[2] Wuxi Ninth People’s Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital),Department of Pharmacy
[3] Wuxi Ninth People’s Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital),Department of Sports Medicine
[4] Department of Pharmacy,Department of Oncology
[5] Wuxi Ninth People’s Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital),undefined
来源：
BMC Health Services Research | / 23卷
关键词：
Chronic lymphocytic leukemia; Cost effectiveness; Ibrutinib; Bendamustine; Rituximab; Quality adjusted life-year;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 33 条
  • [1] Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
    Hong, Yuan
    Chen, Xichuang
    Hong, Yuanquan
    Xiao, Xingfang
    Wang, Yan
    You, Xiaohong
    Mi, Jingyi
    Zhou, Tao
    Zheng, Panpan
    Huang, Zhihu
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [2] No benefit from adding rituximab to ibrutinib in relapsed or refractory chronic lymphocytic leukemia or 17p deletion/TP53 mutation
    Calleja, Anne
    HEMATOLOGIE, 2019, 25 (03): : 131 - 132
  • [3] ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Lachaine, J.
    Kouroukis, C. T.
    VALUE IN HEALTH, 2016, 19 (03) : A248 - A248
  • [4] CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations
    Sharman, Jeff P.
    Laurenti, Luca
    Ferrant, Emmanuelle
    Montero, Luis Felipe Casado
    Mulligan, Stephen P.
    Harrup, Rosemary
    Opat, Stephen
    Ibatici, Adalberto
    Marasca, Roberto
    Sportoletti, Paolo
    Lefebure, Marcus
    Boyer, Michelle
    Jiang, Yanwen
    Barlera, Simona
    Cazares, Oscar
    Morschhauser, Franck
    BLOOD, 2024, 144 : 3237 - 3238
  • [5] Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials
    Allan, John N.
    Shanafelt, Tait
    Wiestner, Adrian
    Moreno, Carol
    O'Brien, Susan M.
    Braggio, Esteban
    Liu, Emily
    Dean, James P.
    Lai, Dominic
    Ahn, Inhye E.
    BLOOD, 2020, 136
  • [6] A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
    Mato, Anthony R.
    Tang, Boxiong
    Azmi, Soraya
    Yang, Keri
    Zhang, Xiaojuan
    Stern, Jennifer C.
    Hedrick, Eric
    Huang, Jane
    Sharman, Jeff P.
    HAEMATOLOGICA, 2022, 107 (11) : 2630 - 2640
  • [7] A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
    Mato, Anthony R.
    Tang, Boxiong
    Azmi, Soraya
    Yang, Keri
    Zhang, Xiaojuan
    Stern, Jennifer C.
    Hedrick, Eric
    Huang, Jane
    Sharman, Jeff P.
    HAEMATOLOGICA, 2022, 107 : 2630 - 2640
  • [8] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
    Jain, Nitin
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Bose, Prithviraj
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Sasaki, Koji
    Garg, Naveen
    Wang, Xuemei
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Lopez, Wanda
    Ayala, Ana
    Plunkett, William
    Gandhi, Varsha
    Kantarjian, Hagop M.
    O'Brien, Susan
    Keating, Michael J.
    Wierda, William G.
    BLOOD, 2019, 134
  • [9] Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p
    Barnes, James, I
    Divi, Vasu
    Begaye, Adrian
    Wong, Russell
    Coutre, Steven
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    BLOOD ADVANCES, 2018, 2 (15) : 1946 - 1956
  • [10] OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY
    Visentin, A.
    Pravato, S.
    Mauro, F. R.
    Pietrasanta, D.
    Fresa, A.
    Vitale, C.
    Ciolli, S.
    Cassin, R.
    Cibien, F.
    Sportoletti, P.
    Gentile, M.
    Rigolin, G. M.
    Quaglia, F. M.
    Murru, R.
    Gozzetti, A.
    Molica, S.
    Marchetti, M.
    Scarfo, L.
    Guardalben, E.
    Avitabile, A.
    Reda, G.
    Coscia, M.
    Laurenti, L.
    Pizzolo, G.
    Semenzato, G.
    Foa, R.
    Cuneo, A.
    Trentin, L.
    HAEMATOLOGICA, 2021, 106 (10) : 62 - 63
1234